

## UK CLL Trials 2019

	Patients considered fit for FCR	Patients considered unfit for FCR
Untreated patients	FLAIR trial	Acerta ACE-CL-007 (closed for recruitment) GLOW CLL3011 (closed for recruitment) BGB-3111-304 (closed for recruitment)
Untreated patients with 17p del	FLAIR I+V arm for 17p/P53mutated (when amendment is approved)	BGB-3111-304 (Cohort A: closed for recruitment)
Previously treated patients	BGB-3111-305	BGB-3111-305
Previously treated high risk patients	Acerta ACE-CL-006 (closed for recruitment)	Acerta ACE-CL-006 (closed for recruitment)
Relapsed/Refractory CLL	ACE-CL-110  Sunesis Phase 1/Phase 2 dose escalation and cohort expansion study of SNS062 in patients with B cell malignancies  Zuma-8 CAR-T Cell Trial	ACE-CL-110  Sunesis Phase 1/Phase 2 dose escalation and cohort expansion study of SNS062 in patients with B cell malignancies  Zuma-8 CAR-T Cell Trial
Consolidation/ Maintenance	GA-101 (obinutuzumab) monoclonal Antibody as Consolidation Therapy In CLL (closed for recruitment) In design INTERRUPT Trial (Ibrutinib)	GA-101 (obinutuzumab) monoclonal Antibody as Consolidation Therapy In CLL (closed for recruitment) In Design INTERRUPT Trial (Ibrutinib)
Richter's Transformation Frontline and relapsed	STELLAR: CHOP-R vs CHOP-R in combination with ACP-196 Bloodwise TAP Trial	